These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33687790)

  • 1. Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials.
    Liao B; Chen Y; Chigutsa F; Piras de Oliveira C
    Diabetes Obes Metab; 2021 Jul; 23(7):1571-1579. PubMed ID: 33687790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trials.
    Piras de Oliveira C; Dellva MA; Bue-Valleskey J; Chang AM; Liao B
    J Diabetes Complications; 2024 Jan; 38(1):108648. PubMed ID: 38035641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study.
    Wang X; Wu G; Shen D; Zhang X; Yang W
    Adv Ther; 2022 Jun; 39(6):2820-2830. PubMed ID: 35430674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.
    Yuan L; Luo Y; Luo Y; Ding B; Zhang P; Ma J; Wu J
    Front Endocrinol (Lausanne); 2024; 15():1364585. PubMed ID: 38774225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
    Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
    Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.
    Bonora E
    Int J Clin Pract Suppl; 2002 Jul; (129):5-11. PubMed ID: 12166607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis.
    Ma J; Lei M; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2020 Sep; 37(9):3816-3826. PubMed ID: 32671687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial glucose regulation: new data and new implications.
    Leiter LA; Ceriello A; Davidson JA; Hanefeld M; Monnier L; Owens DR; Tajima N; Tuomilehto J;
    Clin Ther; 2005; 27 Suppl B():S42-56. PubMed ID: 16519037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
    Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
    Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.
    Ma J; Yan X; Feng Q; Liu W; Pérez Manghi F; García-Hernández P; Wang G; Xu J; Yuan Y; Zhou Z
    Diabetes Obes Metab; 2024 Jan; 26(1):311-318. PubMed ID: 37871985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes - a nationwide evaluation of clinical practice.
    Mungreiphy NK; Mamza J; Lakhdar AF; Bannister M; Elliott J; Idris I
    Curr Med Res Opin; 2015 Mar; 31(3):493-501. PubMed ID: 25597325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
    Li L; Yang T; Xue Y; Ruan P; Du J; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2022 Jan; 39(1):421-429. PubMed ID: 34757600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
    Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
    Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
    Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
    Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.